Cancer Chemotherapy Reviews Indexed in
EMBASE/Excerpta Medica
Thursday, October 18, 2018 
ISSN: 2339-8728
Subscribers area
Home Editorial Board Journal Contents Subscriptions Contact Us Authors Instructions
<<< back |

Bibliography Revision on Hepatocarcinoma

April-June 2017, Volume 12, Number 2
Lynda Vásconez
Medical Oncology Service, Universidad Católica de Argentina, Argentina

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and its increasing incidence worldwide is a cause for concern. Fortunately, advances in diagnostic and therapeutic approaches have contributed to earlier detection and treatment. Improved survival rates among HCC patients also reflect significant advances in available treatment options. Advances in surgical techniques are pushing the boundaries of resection for localized disease, and progress in the field of transplantation has led to refinements in listing criteria and improved post-transplant outcomes. The evolving field of locoregional therapies, including percutaneous ablation and transarterial chemoembolization, continues to provide novel therapeutic options that can be used instead of, or in addition to, surgical approaches. Recent advances in systemic multi-kinase inhibitor therapies have also demonstrated significant benefits for advanced-stage disease, and these therapies also show promising results as adjuvant treatments for earlier-stage disease. This review provides an update on the management of HCC, with a focus on revised guidelines for screening and an in-depth discussion of emerging novel therapies.

Key words:
Hepatocellular carcinoma (HCC). Transplantation. Locoregional therapy. Percutaneous ablation. Transarterial chemoembolization. Systemic multi-kinase inhibitor.
[Buy Article]
Mallorca, 310 - 08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
© Permanyer Publications | Made & Powered by IMMA PUIG | Privacy Policy - Legal notice